Humacyte (NASDAQ:HUMA) versus DBV Technologies (NASDAQ:DBVT) Critical Survey

Humacyte (NASDAQ:HUMA) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for Humacyte and DBV Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1	1	6	0	2.62
DBV Technologies	1	0	5	0	2.67

Humacyte currently has a consensus target price of $4.96, suggesting a potential upside of 800.96%. DBV Technologies has a consensus target price of $45.25, suggesting a potential upside of 295.58%. Given Humacyte’s higher possible upside, equities analysts plainly believe Humacyte is more favorable than DBV Technologies.

Valuation & Earnings

This table compares Humacyte and DBV Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04 million	75.03	-$40.83 million	($0.49)	-1.12
DBV Technologies	$5.64 million	127.53	-$146.95 million	($3.01)	-3.80

Humacyte has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Humacyte and DBV Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
DBV Technologies	-5,392.17%	-120.95%	-88.35%

Volatility & Risk

Humacyte has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Summary

Humacyte beats DBV Technologies on 8 of the 14 factors compared between the two stocks.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

About DBV Technologies

DBV Technologies S.A. (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system. DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children. The company has also investigated its Viaskin platform in other allergy indications, including cow’s milk protein allergy.